Switch theme
Sign up to access all valuation multiples
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
1990
8
LTM Revenue n/a
LTM EBITDA n/a
$34.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cyclo Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cyclo Therapeutics achieved revenue of $1.1M and an EBITDA of -$20.0M.
Cyclo Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cyclo Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.1M | n/a | XXX | XXX | XXX |
| Gross Profit | $1.4M | $1.2M | XXX | XXX | XXX |
| Gross Margin | 133% | NaN% | XXX | XXX | XXX |
| EBITDA | -$20.0M | n/a | XXX | XXX | XXX |
| EBITDA Margin | -1861% | NaN% | XXX | XXX | XXX |
| Net Profit | -$14.3M | -$15.5M | XXX | XXX | XXX |
| Net Margin | -1327% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Cyclo Therapeutics's stock price is $1.
Cyclo Therapeutics has current market cap of $23.2M, and EV of $34.5M.
See Cyclo Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $34.5M | $23.2M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Cyclo Therapeutics has market cap of $23.2M and EV of $34.5M.
Cyclo Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cyclo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cyclo Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $34.5M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCyclo Therapeutics's NTM/LTM revenue growth is n/a
Cyclo Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $2.6M for the same period.
Over next 12 months, Cyclo Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cyclo Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cyclo Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $2.6M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 526% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1318% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1955% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cyclo Therapeutics acquired XXX companies to date.
Last acquisition by Cyclo Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Cyclo Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cyclo Therapeutics founded? | Cyclo Therapeutics was founded in 1990. |
| Where is Cyclo Therapeutics headquartered? | Cyclo Therapeutics is headquartered in United States of America. |
| How many employees does Cyclo Therapeutics have? | As of today, Cyclo Therapeutics has 8 employees. |
| Who is the CEO of Cyclo Therapeutics? | Cyclo Therapeutics's CEO is Mr. N. Scott Fine. |
| Is Cyclo Therapeutics publicy listed? | Yes, Cyclo Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Cyclo Therapeutics? | Cyclo Therapeutics trades under CYTH ticker. |
| When did Cyclo Therapeutics go public? | Cyclo Therapeutics went public in 2020. |
| Who are competitors of Cyclo Therapeutics? | Similar companies to Cyclo Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cyclo Therapeutics? | Cyclo Therapeutics's current market cap is $23.2M |
| Is Cyclo Therapeutics profitable? | Yes, Cyclo Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
